Entecavir (Baraclude) Multicenter Evaluation Sheds Further Light on Anti-HIV Activity of At the 2007 Conference on Retroviruses and Opportunistic Infections (CROI), researchers reported that entecavir (Baraclude), a nucleoside analog approved for the treatment of...
Multicenter Evaluation Sheds Further Light on Anti-HIV Activity of Entecavir (Baraclude) At the 2007 Conference on Retroviruses and Opportunistic Infections (CROI), researchers reported that entecavir (Baraclude), a nucleoside analog approved for the treatment of chronic hepatitis B virus (HBV) infection,....
Push for more HIV screens to drive Gilead's growth According to the Associated Press, increasing efforts by U.S.cities such as New York to expand HIV testing will boost Gilead Sciences' bottomline, since more than 80 percent of the nation's newly diagnosed HIV patients begin treatment...
Push for more HIV screens to drive Gilead's growth Increasing efforts by U.S.cities such as New York to expand HIV testing will boost Gilead Sciences' bottomline, since more than 80 percent of the nation's newly diagnosed HIV patients begin treatment with either the company's Truvada or...
Push for more HIV screens to drive Gilead's growth Increasing efforts by U.S.cities such as New York to expand HIV testing will boost Gilead Sciences' bottomline, since more than 80 percent of the nation's newly diagnosed HIV patients begin treatment with either the company's Truvada or...
Push for more HIV screens to drive Gilead's growth NEW YORK - Increasing efforts by U.S.cities such as New York to expand HIV testing will boost Gilead Sciences' bottomline, since more than 80 percent of the nation's newly diagnosed HIV patients begin treatment with either the company's...
CDC, cities' push for increased HIV screening will boost Gilead's drug sales - 4:00 p.m.NEW YORK (AP) - Increasing efforts by U.S.
cities such as New York to expand HIV testing will boost Gilead Sciences' bottomline, since more than 80 percent of the nation's newly diagnosed HIV patients begin treatment with...
Push for more HIV screens to drive Gilead's growth Foster City, Calif.-based Gilead generates most of its revenue from its HIV franchise, which includes the drugs Viread, Emtriva, Truvada (a combination of Viread and Emtriva) and Atripla, which combines Truvada and Bristol-Myers...
Adding Tenofovir (Viread) plus Emtricitabine (Emtriva) to Short-course Zidovudine (Retrovir) and Single-dose N By Liz Highleyman A short course of and single-dose nevirapine (Viramune) at the time of delivery have been shown to reduce the risk of , but some babies still become infected.As described in the June 1, 2008 Journal of Acquired Immune...
Price of Four HIV Meds Frozen for ADAPs, Other U.S. Programs Pharmaceutical companies Boehringer Ingelheim and Gilead Sciences are freezing the prices of their antiretroviral drugs for select agencies in the U.S., the AIDS Healthcare Foundation announced on Tuesday, Bloomberg reports.Gilead will...
Ahead of the Bell: Biotechnology companies A Deutsche Bank analyst assigned 'Buy' ratings Thursday on biotechnology companies Genentech Inc., Gilead Sciences Inc.and Amgen Inc.
In starting coverage of the sector, Mark Schoenebaum said shares of Amgen and Gilead should both rise...
Ahead of the Bell: Biotechnology companies A Deutsche Bank analyst assigned 'Buy' ratings Thursday on biotechnology companies Genentech Inc., Gilead Sciences Inc.and Amgen Inc.
In starting coverage of the sector, Mark Schoenebaum said shares of Amgen (nasdaq: AMGN - news -...
Analyst rates Genentech, Gilead and Amgen at 'Buy' in starting biotechnology coverage NEW YORK (AP) - A Deutsche Bank analyst assigned 'Buy' ratings Thursday on biotechnology companies Genentech Inc., Gilead Sciences Inc.and Amgen Inc.
In starting coverage of the sector, Mark Schoenebaum said shares of Amgen and Gilead...
Ahead of the Bell: Biotechnology companies NEW YORK - A Deutsche Bank analyst assigned 'Buy' ratings Thursday on biotechnology companies Genentech Inc., Gilead Sciences Inc.and Amgen Inc.
In starting coverage of the sector, Mark Schoenebaum said shares of Amgen and Gilead should...
Ahead of the Bell: Biotechnology companies NEW YORK (AP) -- A Deutsche Bank analyst assigned 'Buy' ratings Thursday on biotechnology companies Genentech Inc., Gilead Sciences Inc.and Amgen Inc.In starting coverage of the sector, Mark Schoenebaum said shares of Amgen and Gilead...
HAART Regimen Changes Due to Drug Toxicities in HIV Positive People with Virological Suppression HAART Regimens Changes Due to Drug Toxicities in HIV Positive People with Virological Suppression Many prior studies have looked at switching various antiretroviral drug regimens due to virological failure or side effects, but few...
Gilead Sciences to freeze price for some HIV drugs Gilead Sciences Inc.is freezing prices on most AIDS/HIV drugs it sells to government drug-assistance programs, and limiting even patients with private insurance to payments of $50 per month.
In response to AIDS patient advocacy groups,...
Gilead Sciences to freeze price for some HIV drugs Gilead Sciences Inc.is freezing prices on most AIDS/HIV drugs it sells to government drug-assistance programs, and limiting even patients with private insurance to payments of $50 per month.
In response to AIDS patient advocacy groups,...
Boehringer, Gilead freeze antiretroviral prices for some U.S. agencies Pharmaceutical companies Boehringer Ingelheim and Gilead Sciences are freezing the prices of their antiretroviral drugs for select agencies in the U.S., the announced on Tuesday, Bloomberg reports.Gilead will freeze the prices on its...
Boehringer, Gilead Freeze Antiretroviral Prices For Some U.S. Agencies Current Article Ratings: Patient / Public: Health Professional: Article Opinions: 0 posts Pharmaceutical companies Boehringer Ingelheim and Gilead Sciences are freezing the prices of their antiretroviral drugs for select agencies in the U.S....
Boehringer, Gilead Freeze Antiretroviral Prices for Some U.S. Agencies Pharmaceutical companies Boehringer Ingelheim and Gilead Sciences are freezing the prices of their antiretroviral drugs for select agencies in the U.S., the announced on Tuesday, Bloomberg reports.Gilead will freeze the prices on its...
NIAID Halts ACTG 5175 Clinical Trial Arm Receiving Once-daily Atazanavir (Reyataz), Emtricitabine (Emtriva), a _ NIAID Halts ACTG 5175 Clinical Trial Arm Receiving Once-daily Atazanavir (Reyataz), Emtricitabine (Emtriva), a.
Low rate of toxicity-related treatment change suggests HIV treatment tolerable in the long-term HIV-positive patients with an undetectable viral load infrequently change their anti-HIV treatment because of side-effects nowadays, according to the results of a British study published in the May 31st edition of AIDS.The study found...
HIV/AIDS Update - Tentative approval of generic emtricitabine capsules FDA granted tentative approval for a generic formulation of emtricitabine capsules, 200 mg, manufactured by Aurobindo Pharma Limited, Hyberdad, India, for use in combination with other antiretrovirals in the treatment of HIV infection.The...
Gilead sees positive patent decision on Viread NEW YORK (AP) - Biotechnology company Gilead Sciences Inc.said late Tuesday the U.S.
Patent and Trademark Office upheld one of four key patents for its HIV drug Viread.
The decision is part of an ongoing process after the Patent...
